nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—AOX1—Methotrexate—muscle cancer	0.796	1	CbGbCtD
Brimonidine—AOX1—Effects of Nitric Oxide—MB—muscle cancer	0.0369	0.736	CbGpPWpGaD
Brimonidine—Blindness—Vincristine—muscle cancer	0.00422	0.0275	CcSEcCtD
Brimonidine—Cyanosis—Etoposide—muscle cancer	0.00267	0.0174	CcSEcCtD
Brimonidine—Rash papular—Doxorubicin—muscle cancer	0.00263	0.0171	CcSEcCtD
Brimonidine—Respiratory failure—Vincristine—muscle cancer	0.00238	0.0155	CcSEcCtD
Brimonidine—Apnoea—Etoposide—muscle cancer	0.00223	0.0145	CcSEcCtD
Brimonidine—Coma—Vincristine—muscle cancer	0.00213	0.0139	CcSEcCtD
Brimonidine—Osteoporosis—Methotrexate—muscle cancer	0.00202	0.0132	CcSEcCtD
Brimonidine—Muscle relaxant therapy—Doxorubicin—muscle cancer	0.00197	0.0128	CcSEcCtD
Brimonidine—Lethargy—Dactinomycin—muscle cancer	0.00194	0.0126	CcSEcCtD
Brimonidine—Hypotonia—Doxorubicin—muscle cancer	0.00187	0.0121	CcSEcCtD
Brimonidine—Hypoxia—Methotrexate—muscle cancer	0.00178	0.0116	CcSEcCtD
Brimonidine—Blindness—Doxorubicin—muscle cancer	0.00177	0.0115	CcSEcCtD
Brimonidine—Hypothermia—Doxorubicin—muscle cancer	0.00175	0.0114	CcSEcCtD
Brimonidine—Body temperature decreased—Doxorubicin—muscle cancer	0.00175	0.0114	CcSEcCtD
Brimonidine—Lacrimation—Doxorubicin—muscle cancer	0.00167	0.0109	CcSEcCtD
Brimonidine—Burning sensation—Methotrexate—muscle cancer	0.00163	0.0106	CcSEcCtD
Brimonidine—Cyanosis—Methotrexate—muscle cancer	0.0016	0.0104	CcSEcCtD
Brimonidine—Swelling—Etoposide—muscle cancer	0.00156	0.0101	CcSEcCtD
Brimonidine—Keratitis—Doxorubicin—muscle cancer	0.00151	0.00985	CcSEcCtD
Brimonidine—Burning sensation—Doxorubicin—muscle cancer	0.00141	0.0092	CcSEcCtD
Brimonidine—Apnoea—Methotrexate—muscle cancer	0.00134	0.0087	CcSEcCtD
Brimonidine—Pharyngitis—Dactinomycin—muscle cancer	0.0013	0.00848	CcSEcCtD
Brimonidine—Depression—Vincristine—muscle cancer	0.0013	0.00848	CcSEcCtD
Brimonidine—Scotoma—Doxorubicin—muscle cancer	0.00129	0.00841	CcSEcCtD
Brimonidine—Feeling hot—Doxorubicin—muscle cancer	0.00125	0.00814	CcSEcCtD
Brimonidine—Flushing—Dactinomycin—muscle cancer	0.00122	0.00793	CcSEcCtD
Brimonidine—Stinging—Doxorubicin—muscle cancer	0.00121	0.00789	CcSEcCtD
Brimonidine—AOX1—Tryptophan metabolism—MDM2—muscle cancer	0.0012	0.0238	CbGpPWpGaD
Brimonidine—Respiratory failure—Methotrexate—muscle cancer	0.00115	0.00751	CcSEcCtD
Brimonidine—Erythema—Dactinomycin—muscle cancer	0.00114	0.00744	CcSEcCtD
Brimonidine—Vasodilation—Doxorubicin—muscle cancer	0.00112	0.00727	CcSEcCtD
Brimonidine—Vasodilation procedure—Doxorubicin—muscle cancer	0.00112	0.00727	CcSEcCtD
Brimonidine—Cardiac disorder—Vincristine—muscle cancer	0.00109	0.00709	CcSEcCtD
Brimonidine—Arthropathy—Doxorubicin—muscle cancer	0.00108	0.00703	CcSEcCtD
Brimonidine—Lacrimation increased—Doxorubicin—muscle cancer	0.00106	0.00693	CcSEcCtD
Brimonidine—Angiopathy—Vincristine—muscle cancer	0.00106	0.00693	CcSEcCtD
Brimonidine—Mediastinal disorder—Vincristine—muscle cancer	0.00106	0.00688	CcSEcCtD
Brimonidine—Coma—Methotrexate—muscle cancer	0.00104	0.00674	CcSEcCtD
Brimonidine—Mental disorder—Vincristine—muscle cancer	0.00103	0.00669	CcSEcCtD
Brimonidine—Myalgia—Dactinomycin—muscle cancer	0.000973	0.00633	CcSEcCtD
Brimonidine—Dermatitis contact—Doxorubicin—muscle cancer	0.00097	0.00631	CcSEcCtD
Brimonidine—Discomfort—Dactinomycin—muscle cancer	0.000961	0.00626	CcSEcCtD
Brimonidine—Diabetes mellitus—Methotrexate—muscle cancer	0.000946	0.00616	CcSEcCtD
Brimonidine—Oedema—Dactinomycin—muscle cancer	0.000933	0.00607	CcSEcCtD
Brimonidine—Infection—Dactinomycin—muscle cancer	0.000926	0.00603	CcSEcCtD
Brimonidine—Dry eye—Doxorubicin—muscle cancer	0.000906	0.0059	CcSEcCtD
Brimonidine—Coma—Doxorubicin—muscle cancer	0.000897	0.00584	CcSEcCtD
Brimonidine—Eye disorder—Etoposide—muscle cancer	0.000888	0.00578	CcSEcCtD
Brimonidine—Flushing—Etoposide—muscle cancer	0.000882	0.00574	CcSEcCtD
Brimonidine—Cardiac disorder—Etoposide—muscle cancer	0.000882	0.00574	CcSEcCtD
Brimonidine—Hypertension—Vincristine—muscle cancer	0.000881	0.00574	CcSEcCtD
Brimonidine—Myalgia—Vincristine—muscle cancer	0.000869	0.00566	CcSEcCtD
Brimonidine—Visual disturbance—Methotrexate—muscle cancer	0.000868	0.00565	CcSEcCtD
Brimonidine—Angiopathy—Etoposide—muscle cancer	0.000862	0.00561	CcSEcCtD
Brimonidine—Immune system disorder—Etoposide—muscle cancer	0.000858	0.00559	CcSEcCtD
Brimonidine—Mediastinal disorder—Etoposide—muscle cancer	0.000856	0.00557	CcSEcCtD
Brimonidine—Abnormal vision—Doxorubicin—muscle cancer	0.000856	0.00557	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00085	0.00553	CcSEcCtD
Brimonidine—Lethargy—Methotrexate—muscle cancer	0.000839	0.00547	CcSEcCtD
Brimonidine—Oedema—Vincristine—muscle cancer	0.000833	0.00542	CcSEcCtD
Brimonidine—Infection—Vincristine—muscle cancer	0.000828	0.00539	CcSEcCtD
Brimonidine—Osteoarthritis—Methotrexate—muscle cancer	0.000823	0.00536	CcSEcCtD
Brimonidine—Diabetes mellitus—Doxorubicin—muscle cancer	0.000819	0.00533	CcSEcCtD
Brimonidine—Nervous system disorder—Vincristine—muscle cancer	0.000817	0.00532	CcSEcCtD
Brimonidine—Dysgeusia—Etoposide—muscle cancer	0.00081	0.00527	CcSEcCtD
Brimonidine—Fatigue—Dactinomycin—muscle cancer	0.000804	0.00523	CcSEcCtD
Brimonidine—Pain—Dactinomycin—muscle cancer	0.000798	0.00519	CcSEcCtD
Brimonidine—Eye pain—Doxorubicin—muscle cancer	0.000789	0.00514	CcSEcCtD
Brimonidine—Hypotension—Vincristine—muscle cancer	0.000779	0.00507	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000759	0.00494	CcSEcCtD
Brimonidine—Insomnia—Vincristine—muscle cancer	0.000754	0.00491	CcSEcCtD
Brimonidine—Paraesthesia—Vincristine—muscle cancer	0.000748	0.00487	CcSEcCtD
Brimonidine—Loss of consciousness—Etoposide—muscle cancer	0.000727	0.00473	CcSEcCtD
Brimonidine—Lethargy—Doxorubicin—muscle cancer	0.000727	0.00473	CcSEcCtD
Brimonidine—Cough—Etoposide—muscle cancer	0.000722	0.0047	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Vincristine—muscle cancer	0.000719	0.00468	CcSEcCtD
Brimonidine—Fatigue—Vincristine—muscle cancer	0.000718	0.00468	CcSEcCtD
Brimonidine—Hypertension—Etoposide—muscle cancer	0.000714	0.00465	CcSEcCtD
Brimonidine—Pain—Vincristine—muscle cancer	0.000713	0.00464	CcSEcCtD
Brimonidine—Osteoarthritis—Doxorubicin—muscle cancer	0.000712	0.00464	CcSEcCtD
Brimonidine—Chest pain—Etoposide—muscle cancer	0.000704	0.00458	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000699	0.00455	CcSEcCtD
Brimonidine—Discomfort—Etoposide—muscle cancer	0.000696	0.00453	CcSEcCtD
Brimonidine—AOX1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—muscle cancer	0.000692	0.0138	CbGpPWpGaD
Brimonidine—Face oedema—Doxorubicin—muscle cancer	0.000688	0.00448	CcSEcCtD
Brimonidine—Hypersensitivity—Dactinomycin—muscle cancer	0.000687	0.00447	CcSEcCtD
Brimonidine—Infection—Etoposide—muscle cancer	0.000671	0.00437	CcSEcCtD
Brimonidine—Asthenia—Dactinomycin—muscle cancer	0.000669	0.00436	CcSEcCtD
Brimonidine—Tachycardia—Etoposide—muscle cancer	0.000659	0.00429	CcSEcCtD
Brimonidine—Skin disorder—Etoposide—muscle cancer	0.000656	0.00427	CcSEcCtD
Brimonidine—Dry skin—Doxorubicin—muscle cancer	0.000653	0.00425	CcSEcCtD
Brimonidine—Nasopharyngitis—Doxorubicin—muscle cancer	0.000637	0.00415	CcSEcCtD
Brimonidine—Drowsiness—Methotrexate—muscle cancer	0.000634	0.00413	CcSEcCtD
Brimonidine—Depression—Methotrexate—muscle cancer	0.000632	0.00412	CcSEcCtD
Brimonidine—Hypotension—Etoposide—muscle cancer	0.000631	0.00411	CcSEcCtD
Brimonidine—Conjunctivitis—Methotrexate—muscle cancer	0.000616	0.00401	CcSEcCtD
Brimonidine—Influenza—Doxorubicin—muscle cancer	0.000616	0.00401	CcSEcCtD
Brimonidine—Hypersensitivity—Vincristine—muscle cancer	0.000614	0.004	CcSEcCtD
Brimonidine—Paraesthesia—Etoposide—muscle cancer	0.000606	0.00395	CcSEcCtD
Brimonidine—Dyspnoea—Etoposide—muscle cancer	0.000602	0.00392	CcSEcCtD
Brimonidine—Somnolence—Etoposide—muscle cancer	0.0006	0.00391	CcSEcCtD
Brimonidine—Asthenia—Vincristine—muscle cancer	0.000598	0.00389	CcSEcCtD
Brimonidine—Bronchitis—Doxorubicin—muscle cancer	0.000592	0.00385	CcSEcCtD
Brimonidine—Rash—Dactinomycin—muscle cancer	0.000588	0.00383	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Etoposide—muscle cancer	0.000583	0.00379	CcSEcCtD
Brimonidine—Fatigue—Etoposide—muscle cancer	0.000582	0.00379	CcSEcCtD
Brimonidine—Pain—Etoposide—muscle cancer	0.000577	0.00376	CcSEcCtD
Brimonidine—Pharyngitis—Methotrexate—muscle cancer	0.000565	0.00368	CcSEcCtD
Brimonidine—Nausea—Dactinomycin—muscle cancer	0.000554	0.00361	CcSEcCtD
Brimonidine—Dizziness—Vincristine—muscle cancer	0.000551	0.00359	CcSEcCtD
Brimonidine—Drowsiness—Doxorubicin—muscle cancer	0.000549	0.00357	CcSEcCtD
Brimonidine—Visual impairment—Methotrexate—muscle cancer	0.000548	0.00357	CcSEcCtD
Brimonidine—Conjunctivitis—Doxorubicin—muscle cancer	0.000534	0.00347	CcSEcCtD
Brimonidine—Eye disorder—Methotrexate—muscle cancer	0.000532	0.00346	CcSEcCtD
Brimonidine—Cardiac disorder—Methotrexate—muscle cancer	0.000528	0.00344	CcSEcCtD
Brimonidine—Rash—Vincristine—muscle cancer	0.000525	0.00342	CcSEcCtD
Brimonidine—Dermatitis—Vincristine—muscle cancer	0.000525	0.00342	CcSEcCtD
Brimonidine—Headache—Vincristine—muscle cancer	0.000522	0.0034	CcSEcCtD
Brimonidine—Angiopathy—Methotrexate—muscle cancer	0.000516	0.00336	CcSEcCtD
Brimonidine—Sinusitis—Doxorubicin—muscle cancer	0.000515	0.00335	CcSEcCtD
Brimonidine—Immune system disorder—Methotrexate—muscle cancer	0.000514	0.00335	CcSEcCtD
Brimonidine—Mediastinal disorder—Methotrexate—muscle cancer	0.000513	0.00334	CcSEcCtD
Brimonidine—Bradycardia—Doxorubicin—muscle cancer	0.000502	0.00327	CcSEcCtD
Brimonidine—Mental disorder—Methotrexate—muscle cancer	0.000499	0.00325	CcSEcCtD
Brimonidine—Hypersensitivity—Etoposide—muscle cancer	0.000497	0.00324	CcSEcCtD
Brimonidine—Erythema—Methotrexate—muscle cancer	0.000495	0.00323	CcSEcCtD
Brimonidine—Nausea—Vincristine—muscle cancer	0.000495	0.00322	CcSEcCtD
Brimonidine—Rhinitis—Doxorubicin—muscle cancer	0.000494	0.00322	CcSEcCtD
Brimonidine—Pharyngitis—Doxorubicin—muscle cancer	0.000489	0.00318	CcSEcCtD
Brimonidine—Dysgeusia—Methotrexate—muscle cancer	0.000485	0.00316	CcSEcCtD
Brimonidine—Asthenia—Etoposide—muscle cancer	0.000484	0.00315	CcSEcCtD
Brimonidine—Pruritus—Etoposide—muscle cancer	0.000478	0.00311	CcSEcCtD
Brimonidine—Visual impairment—Doxorubicin—muscle cancer	0.000475	0.00309	CcSEcCtD
Brimonidine—Vision blurred—Methotrexate—muscle cancer	0.000467	0.00304	CcSEcCtD
Brimonidine—Eye disorder—Doxorubicin—muscle cancer	0.00046	0.003	CcSEcCtD
Brimonidine—Cardiac disorder—Doxorubicin—muscle cancer	0.000457	0.00298	CcSEcCtD
Brimonidine—Flushing—Doxorubicin—muscle cancer	0.000457	0.00298	CcSEcCtD
Brimonidine—Angiopathy—Doxorubicin—muscle cancer	0.000447	0.00291	CcSEcCtD
Brimonidine—Dizziness—Etoposide—muscle cancer	0.000446	0.00291	CcSEcCtD
Brimonidine—Immune system disorder—Doxorubicin—muscle cancer	0.000445	0.0029	CcSEcCtD
Brimonidine—Mediastinal disorder—Doxorubicin—muscle cancer	0.000444	0.00289	CcSEcCtD
Brimonidine—Arrhythmia—Doxorubicin—muscle cancer	0.00044	0.00287	CcSEcCtD
Brimonidine—Cough—Methotrexate—muscle cancer	0.000432	0.00281	CcSEcCtD
Brimonidine—Mental disorder—Doxorubicin—muscle cancer	0.000432	0.00281	CcSEcCtD
Brimonidine—Erythema—Doxorubicin—muscle cancer	0.000429	0.00279	CcSEcCtD
Brimonidine—Rash—Etoposide—muscle cancer	0.000426	0.00277	CcSEcCtD
Brimonidine—Dermatitis—Etoposide—muscle cancer	0.000425	0.00277	CcSEcCtD
Brimonidine—Headache—Etoposide—muscle cancer	0.000423	0.00275	CcSEcCtD
Brimonidine—Arthralgia—Methotrexate—muscle cancer	0.000422	0.00275	CcSEcCtD
Brimonidine—Myalgia—Methotrexate—muscle cancer	0.000422	0.00275	CcSEcCtD
Brimonidine—Chest pain—Methotrexate—muscle cancer	0.000422	0.00275	CcSEcCtD
Brimonidine—Dysgeusia—Doxorubicin—muscle cancer	0.00042	0.00273	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000419	0.00273	CcSEcCtD
Brimonidine—Discomfort—Methotrexate—muscle cancer	0.000417	0.00271	CcSEcCtD
Brimonidine—Vision blurred—Doxorubicin—muscle cancer	0.000404	0.00263	CcSEcCtD
Brimonidine—Infection—Methotrexate—muscle cancer	0.000402	0.00261	CcSEcCtD
Brimonidine—Nausea—Etoposide—muscle cancer	0.000401	0.00261	CcSEcCtD
Brimonidine—Nervous system disorder—Methotrexate—muscle cancer	0.000396	0.00258	CcSEcCtD
Brimonidine—Skin disorder—Methotrexate—muscle cancer	0.000393	0.00256	CcSEcCtD
Brimonidine—Syncope—Doxorubicin—muscle cancer	0.000385	0.0025	CcSEcCtD
Brimonidine—AOX1—Metabolism—FH—muscle cancer	0.000382	0.00762	CbGpPWpGaD
Brimonidine—Palpitations—Doxorubicin—muscle cancer	0.000379	0.00247	CcSEcCtD
Brimonidine—Hypotension—Methotrexate—muscle cancer	0.000378	0.00246	CcSEcCtD
Brimonidine—Loss of consciousness—Doxorubicin—muscle cancer	0.000377	0.00245	CcSEcCtD
Brimonidine—Cough—Doxorubicin—muscle cancer	0.000374	0.00244	CcSEcCtD
Brimonidine—Hypertension—Doxorubicin—muscle cancer	0.00037	0.00241	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000368	0.0024	CcSEcCtD
Brimonidine—Insomnia—Methotrexate—muscle cancer	0.000366	0.00238	CcSEcCtD
Brimonidine—Arthralgia—Doxorubicin—muscle cancer	0.000365	0.00238	CcSEcCtD
Brimonidine—Chest pain—Doxorubicin—muscle cancer	0.000365	0.00238	CcSEcCtD
Brimonidine—Myalgia—Doxorubicin—muscle cancer	0.000365	0.00238	CcSEcCtD
Brimonidine—Anxiety—Doxorubicin—muscle cancer	0.000364	0.00237	CcSEcCtD
Brimonidine—Paraesthesia—Methotrexate—muscle cancer	0.000363	0.00236	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000363	0.00236	CcSEcCtD
Brimonidine—Discomfort—Doxorubicin—muscle cancer	0.000361	0.00235	CcSEcCtD
Brimonidine—Dyspnoea—Methotrexate—muscle cancer	0.00036	0.00235	CcSEcCtD
Brimonidine—Somnolence—Methotrexate—muscle cancer	0.000359	0.00234	CcSEcCtD
Brimonidine—Dry mouth—Doxorubicin—muscle cancer	0.000357	0.00233	CcSEcCtD
Brimonidine—Dyspepsia—Methotrexate—muscle cancer	0.000356	0.00232	CcSEcCtD
Brimonidine—Oedema—Doxorubicin—muscle cancer	0.00035	0.00228	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000349	0.00227	CcSEcCtD
Brimonidine—Fatigue—Methotrexate—muscle cancer	0.000349	0.00227	CcSEcCtD
Brimonidine—Infection—Doxorubicin—muscle cancer	0.000348	0.00226	CcSEcCtD
Brimonidine—Pain—Methotrexate—muscle cancer	0.000346	0.00225	CcSEcCtD
Brimonidine—Shock—Doxorubicin—muscle cancer	0.000344	0.00224	CcSEcCtD
Brimonidine—Nervous system disorder—Doxorubicin—muscle cancer	0.000343	0.00224	CcSEcCtD
Brimonidine—Tachycardia—Doxorubicin—muscle cancer	0.000342	0.00222	CcSEcCtD
Brimonidine—Skin disorder—Doxorubicin—muscle cancer	0.00034	0.00221	CcSEcCtD
Brimonidine—ADRA2B—G alpha (i) signalling events—CNR1—muscle cancer	0.000335	0.00668	CbGpPWpGaD
Brimonidine—Hypotension—Doxorubicin—muscle cancer	0.000327	0.00213	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000319	0.00208	CcSEcCtD
Brimonidine—Insomnia—Doxorubicin—muscle cancer	0.000317	0.00206	CcSEcCtD
Brimonidine—Paraesthesia—Doxorubicin—muscle cancer	0.000314	0.00205	CcSEcCtD
Brimonidine—ADRA2C—G alpha (i) signalling events—CNR1—muscle cancer	0.000313	0.00624	CbGpPWpGaD
Brimonidine—Dyspnoea—Doxorubicin—muscle cancer	0.000312	0.00203	CcSEcCtD
Brimonidine—Somnolence—Doxorubicin—muscle cancer	0.000311	0.00203	CcSEcCtD
Brimonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.000311	0.0062	CbGpPWpGaD
Brimonidine—Dyspepsia—Doxorubicin—muscle cancer	0.000308	0.00201	CcSEcCtD
Brimonidine—ADRA2B—Hemostasis—ANGPT2—muscle cancer	0.000305	0.00608	CbGpPWpGaD
Brimonidine—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000302	0.00197	CcSEcCtD
Brimonidine—Fatigue—Doxorubicin—muscle cancer	0.000302	0.00197	CcSEcCtD
Brimonidine—Pain—Doxorubicin—muscle cancer	0.000299	0.00195	CcSEcCtD
Brimonidine—Hypersensitivity—Methotrexate—muscle cancer	0.000298	0.00194	CcSEcCtD
Brimonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.000291	0.00579	CbGpPWpGaD
Brimonidine—Asthenia—Methotrexate—muscle cancer	0.00029	0.00189	CcSEcCtD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—IGF2—muscle cancer	0.000288	0.00574	CbGpPWpGaD
Brimonidine—Pruritus—Methotrexate—muscle cancer	0.000286	0.00186	CcSEcCtD
Brimonidine—ADRA2C—Hemostasis—ANGPT2—muscle cancer	0.000285	0.00568	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—IGF2—muscle cancer	0.000269	0.00536	CbGpPWpGaD
Brimonidine—Dizziness—Methotrexate—muscle cancer	0.000267	0.00174	CcSEcCtD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.000267	0.00531	CbGpPWpGaD
Brimonidine—Hypersensitivity—Doxorubicin—muscle cancer	0.000258	0.00168	CcSEcCtD
Brimonidine—Rash—Methotrexate—muscle cancer	0.000255	0.00166	CcSEcCtD
Brimonidine—Dermatitis—Methotrexate—muscle cancer	0.000255	0.00166	CcSEcCtD
Brimonidine—ADRA2A—G alpha (i) signalling events—CNR1—muscle cancer	0.000254	0.00507	CbGpPWpGaD
Brimonidine—Headache—Methotrexate—muscle cancer	0.000253	0.00165	CcSEcCtD
Brimonidine—Asthenia—Doxorubicin—muscle cancer	0.000251	0.00164	CcSEcCtD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.000249	0.00496	CbGpPWpGaD
Brimonidine—Pruritus—Doxorubicin—muscle cancer	0.000248	0.00161	CcSEcCtD
Brimonidine—ADRA2B—GPCR ligand binding—PTCH1—muscle cancer	0.00024	0.00479	CbGpPWpGaD
Brimonidine—Nausea—Methotrexate—muscle cancer	0.00024	0.00156	CcSEcCtD
Brimonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.000236	0.0047	CbGpPWpGaD
Brimonidine—AOX1—Disease—ENO2—muscle cancer	0.000235	0.00469	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—ANGPT2—muscle cancer	0.000232	0.00462	CbGpPWpGaD
Brimonidine—Dizziness—Doxorubicin—muscle cancer	0.000232	0.00151	CcSEcCtD
Brimonidine—ADRA2C—GPCR ligand binding—PTCH1—muscle cancer	0.000225	0.00448	CbGpPWpGaD
Brimonidine—Rash—Doxorubicin—muscle cancer	0.000221	0.00144	CcSEcCtD
Brimonidine—Dermatitis—Doxorubicin—muscle cancer	0.000221	0.00144	CcSEcCtD
Brimonidine—Headache—Doxorubicin—muscle cancer	0.000219	0.00143	CcSEcCtD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—IGF2—muscle cancer	0.000218	0.00435	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—MED12—muscle cancer	0.000216	0.00431	CbGpPWpGaD
Brimonidine—AOX1—Disease—HMGA1—muscle cancer	0.000214	0.00426	CbGpPWpGaD
Brimonidine—Nausea—Doxorubicin—muscle cancer	0.000208	0.00135	CcSEcCtD
Brimonidine—ADRA2B—GPCR ligand binding—CNR1—muscle cancer	0.000203	0.00405	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.000202	0.00403	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—ENO2—muscle cancer	0.000197	0.00393	CbGpPWpGaD
Brimonidine—AOX1—Disease—FOXO4—muscle cancer	0.000192	0.00382	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—CNR1—muscle cancer	0.00019	0.00378	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KIDINS220—muscle cancer	0.000185	0.00369	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—PTCH1—muscle cancer	0.000182	0.00364	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KIDINS220—muscle cancer	0.000173	0.00345	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—FH—muscle cancer	0.000167	0.00332	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—CNR1—muscle cancer	0.000154	0.00307	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—IGF2—muscle cancer	0.000148	0.00296	CbGpPWpGaD
Brimonidine—AOX1—Disease—FOXO1—muscle cancer	0.000142	0.00282	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KIDINS220—muscle cancer	0.000141	0.0028	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—IGF2—muscle cancer	0.000139	0.00276	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—FH—muscle cancer	0.000135	0.0027	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PTCH1—muscle cancer	0.000123	0.00246	CbGpPWpGaD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	0.000121	0.00241	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PTCH1—muscle cancer	0.000115	0.0023	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—CNR1—muscle cancer	0.000115	0.00229	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	0.000113	0.00225	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—IGF2—muscle cancer	0.000113	0.00224	CbGpPWpGaD
Brimonidine—AOX1—Disease—KIT—muscle cancer	0.000108	0.00215	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—CNR1—muscle cancer	0.000107	0.00214	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CNR1—muscle cancer	0.000104	0.00208	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CNR1—muscle cancer	9.73e-05	0.00194	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—MED12—muscle cancer	9.42e-05	0.00188	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PTCH1—muscle cancer	9.36e-05	0.00187	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	9.16e-05	0.00183	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—CNR1—muscle cancer	8.7e-05	0.00173	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ENO2—muscle cancer	8.59e-05	0.00171	CbGpPWpGaD
Brimonidine—AOX1—Disease—MDM2—muscle cancer	8.5e-05	0.00169	CbGpPWpGaD
Brimonidine—AOX1—Disease—PTGS2—muscle cancer	8.19e-05	0.00163	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CNR1—muscle cancer	7.9e-05	0.00158	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—MED12—muscle cancer	7.65e-05	0.00153	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PTCH1—muscle cancer	7.29e-05	0.00145	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ENO2—muscle cancer	6.98e-05	0.00139	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—PTGS2—muscle cancer	6.86e-05	0.00137	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PTCH1—muscle cancer	6.81e-05	0.00136	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FOXO4—muscle cancer	6.27e-05	0.00125	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—VEGFA—muscle cancer	6.22e-05	0.00124	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CNR1—muscle cancer	6.15e-05	0.00123	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FOXO4—muscle cancer	5.86e-05	0.00117	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—VEGFA—muscle cancer	5.81e-05	0.00116	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CNR1—muscle cancer	5.75e-05	0.00115	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PTCH1—muscle cancer	5.53e-05	0.0011	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IGF2—muscle cancer	5.03e-05	0.001	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FOXO4—muscle cancer	4.76e-05	0.000948	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—VEGFA—muscle cancer	4.72e-05	0.000941	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—TP53—muscle cancer	4.7e-05	0.000937	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IGF2—muscle cancer	4.7e-05	0.000937	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CNR1—muscle cancer	4.67e-05	0.00093	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FOXO1—muscle cancer	4.63e-05	0.000923	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—TP53—muscle cancer	4.39e-05	0.000875	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FOXO1—muscle cancer	4.32e-05	0.000862	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IGF2—muscle cancer	3.82e-05	0.000761	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—TP53—muscle cancer	3.57e-05	0.000711	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KIT—muscle cancer	3.53e-05	0.000703	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FOXO1—muscle cancer	3.51e-05	0.0007	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KIT—muscle cancer	3.3e-05	0.000657	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PTGS2—muscle cancer	2.99e-05	0.000596	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MDM2—muscle cancer	2.78e-05	0.000554	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KIT—muscle cancer	2.68e-05	0.000533	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MDM2—muscle cancer	2.6e-05	0.000517	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PTGS2—muscle cancer	2.43e-05	0.000484	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—VEGFA—muscle cancer	2.11e-05	0.00042	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MDM2—muscle cancer	2.11e-05	0.00042	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—VEGFA—muscle cancer	1.97e-05	0.000393	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—VEGFA—muscle cancer	1.6e-05	0.000319	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TP53—muscle cancer	1.59e-05	0.000318	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TP53—muscle cancer	1.49e-05	0.000297	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TP53—muscle cancer	1.21e-05	0.000241	CbGpPWpGaD
